BridgeBio (BBIO) announced the Medicines and Healthcare products Regulatory Agency has granted marketing authorization in the United Kingdom for acoramidis, under the brand name Beyonttra, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy. Acoramidis is a selective small molecule, orally administered near-complete transthyretin stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Bayer (BAYRY) will be responsible for all commercial activity for acoramidis in the UK.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma: Anticipated Q1 Outperformance and Sustained Buy Rating Despite Rising R&D Expenses
- Buy Recommendation for BridgeBio Pharma Driven by Promising ATTR-CM Launch and Late-Stage Portfolio Potential
- BridgeBio price target raised to $53 from $49 at H.C. Wainwright
- BridgeBio management to meet with Piper Sandler
- BridgeBio reports pre-specified subgroup analysis of ATTRibute-CM trial